Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis)
Purpose of the article: The aim of this multicenter observational study is to report data from real world on the use of bimekizumab in patients aged ≥ 65 years with moderate-to-severe plaque psoriasis. Elderly patients are poorly represented in clinical trials on bimekizumab for plaque psoriasis, an...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2393376 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850250001327849472 |
|---|---|
| author | D. Orsini M. Megna C. Assorgi A. Balato R. Balestri N. Bernardini A. Bettacchi T. Bianchelli L. Bianchi G. Buggiani M. Burlando AMG. Brunasso G. Caldarola N. Cameli A. Campanati E. Campione A. Carugno K. Chersi A. Conti A. Costanzo E. Cozzani A. Cuccia D. D’Amico G. Dal Bello E. G. Dall’Olio P. Dapavo C. De Simone E. V. Di Brizzi A. Di Cesare V. Dini M. Esposito E. Errichetti M. C. Fargnoli C. S. Fiorella A. Foti Z. Fratton F. M. Gaiani P. Gisondi R. Giuffrida A. Giunta C. Guarneri A. Legori F. Loconsole P. Malagoli A. Narcisi M. Paolinelli L. Potestio F. Prignano G. Rech A. Rossi N. Skroza F. Trovato M. Venturini A. G. Richetta G. Pellacani A. Dattola |
| author_facet | D. Orsini M. Megna C. Assorgi A. Balato R. Balestri N. Bernardini A. Bettacchi T. Bianchelli L. Bianchi G. Buggiani M. Burlando AMG. Brunasso G. Caldarola N. Cameli A. Campanati E. Campione A. Carugno K. Chersi A. Conti A. Costanzo E. Cozzani A. Cuccia D. D’Amico G. Dal Bello E. G. Dall’Olio P. Dapavo C. De Simone E. V. Di Brizzi A. Di Cesare V. Dini M. Esposito E. Errichetti M. C. Fargnoli C. S. Fiorella A. Foti Z. Fratton F. M. Gaiani P. Gisondi R. Giuffrida A. Giunta C. Guarneri A. Legori F. Loconsole P. Malagoli A. Narcisi M. Paolinelli L. Potestio F. Prignano G. Rech A. Rossi N. Skroza F. Trovato M. Venturini A. G. Richetta G. Pellacani A. Dattola |
| author_sort | D. Orsini |
| collection | DOAJ |
| description | Purpose of the article: The aim of this multicenter observational study is to report data from real world on the use of bimekizumab in patients aged ≥ 65 years with moderate-to-severe plaque psoriasis. Elderly patients are poorly represented in clinical trials on bimekizumab for plaque psoriasis, and real-world studies are important to guide clinical choices.Materials and methods: A retrospective multicenter study was conducted in 33 dermatological outpatient clinics in Italy. Patients aged ≥ 65 years, with moderate-to-severe plaque psoriasis and treated with bimekizumab were enrolled. No exclusion criteria were applied. Bimekizumab was administered following the Italian Guidelines for the management of plaque psoriasis and according to the summary of product characteristics, in adult patients who were candidates for systemic treatments. Overall, 98 subjects were included, and received bimekizumab up to week 36. Clinical and demographic data were collected before the initiation of treatment with bimekizumab. At baseline and each dermatological examination (4, 16, and 36 weeks), clinical outcomes were measured by the following parameters: (1) PASI score; (2) site-specific (scalp, palmoplantar, genital, nail) Psoriasis Global Assessment (PGA). At each visit, the occurrence of any adverse events (AEs) was recorded, including serious AEs and AEs leading to bimekizumab discontinuation.Results: The mean PASI score was 16.6 ± 9.4 at baseline and significantly decreased to 4.3 ± 5.2 after 4 weeks (p < 0.001), and 1.1 ± 1.7 after 16 week (p < 0.001). This level of improvement was maintained after 36 weeks (p < 0.001). PASI ≤2 was recorded in 36 (36.7%) at week 4, 68% and 69.4% at week 16 and 36, respectively. By week 16, 86/98 (87.8%) patients reached PASI75, 71/98 (72.4%) obtained PASI90, and 52/98 (53.1%) PASI100. Binary logistic regression tests showed a significant association of PASI100 by week 4 with lower PASI at baseline. PASI 100 at 16 or 36 weeks was not associated with baseline PASI, obesity, age, gender, previously naïve state, and presence of psoriatic arthritis. Patients naïve to biologics at baseline had similar response to bimekizumab as non-naïve subjects.Conclusions: Bimekizumab is a suitable option for elder patients as it is effective, tolerated and has a convenient schedule. |
| format | Article |
| id | doaj-art-7ef04e4cae9b4655894c0414dffd2eb3 |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-7ef04e4cae9b4655894c0414dffd2eb32025-08-20T01:58:20ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2393376Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis)D. Orsini0M. Megna1C. Assorgi2A. Balato3R. Balestri4N. Bernardini5A. Bettacchi6T. Bianchelli7L. Bianchi8G. Buggiani9M. Burlando10AMG. Brunasso11G. Caldarola12N. Cameli13A. Campanati14E. Campione15A. Carugno16K. Chersi17A. Conti18A. Costanzo19E. Cozzani20A. Cuccia21D. D’Amico22G. Dal Bello23E. G. Dall’Olio24P. Dapavo25C. De Simone26E. V. Di Brizzi27A. Di Cesare28V. Dini29M. Esposito30E. Errichetti31M. C. Fargnoli32C. S. Fiorella33A. Foti34Z. Fratton35F. M. Gaiani36P. Gisondi37R. Giuffrida38A. Giunta39C. Guarneri40A. Legori41F. Loconsole42P. Malagoli43A. Narcisi44M. Paolinelli45L. Potestio46F. Prignano47G. Rech48A. Rossi49N. Skroza50F. Trovato51M. Venturini52A. G. Richetta53G. Pellacani54A. Dattola55Clinical Dermatology Unit, San Gallicano Dermatological Institute (IRCCS), Rome, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyUnit of Dermatology, University of Campania Luigi Vanvitelli, Naples, ItalyDivision of Dermatology, Psoriasis Outpatient Service, APSS – Azienda Provinciale per i Servizi Sanitari, Trento, ItalyDermatology Unit "Daniele Innocenzi", ASL Latina Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, ItalyUOC of Dermatology, Hospital of Macerata, ASUR Marche AV3, Macerata, ItalyDermatology Unit, Istituto Nazionale di Riposo e Cura per Anziani, INRCA-IRCCS Hospital, Ancona, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyS.O.S.D. Dermatologia San Giuseppe, Azienda USL Toscana Centro, Firenze, ItalyDermatologic Clinic, DISSAL, ospedale Policlinico San Martino-IRCCS, Genova, ItalyDepartment of Internal Medicine, Villa Scassi Hospital ASL3, Genoa, ItalySection of Dermatology, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, ItalyClinical Dermatology Unit, San Gallicano Dermatological Institute (IRCCS), Rome, ItalyDermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyDermatology Unit, Department of Medicine and Surgery, University of Insubria, Varese, ItalyDermatology Unit, ASUGI Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, ItalyDermatologic Unit, Department of Surgery, Infermi Hospital of Rimini, AUSL Romagna, Rimini, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyDermatologic Clinic, DISSAL, ospedale Policlinico San Martino-IRCCS, Genova, ItalyUnit of Dermatology, San Donato Hospital, Arezzo, ItalyUOC Dermatologia, AOU "R. Dulbecco" – Catanzaro, Catanzaro, ItalyDermatology Unit, ASST Mantova, Mantova, ItalyDermatology Unit, ASUGI Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, ItalyDepartment of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, ItalySection of Dermatology, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, ItalyUnit of Dermatology, University of Campania Luigi Vanvitelli, Naples, ItalyDepartment of Health Sciences, Dermatology Session, University of Florence, Florence, ItalyDermatology Unit, Department of Clinical and Experimental Medicine, Ospedale Santa Chiara, Pisa, ItalyBiotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy.;Institute of Dermatology, Department of Medicine, University of Udine, Udine, ItalyBiotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy.;Dermatology Unit - Oncology and Ematology Department, PO M.R Dimiccoli, Barletta, ItalyUnit of Dermatology and Cosmetology, IRCCS Ospedale San Raffaele, Milan, ItalyInstitute of Dermatology, Department of Medicine, University of Udine, Udine, ItalyDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, ItalyDepartment of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, ItalyDepartment of Clinical and Experimental Medicine, Dermatology, University of Messina, Messina, ItalyS.O.S.D. Dermatologia San Giuseppe, Azienda USL Toscana Centro, Firenze, ItalyDepartment of Biomedical, Dental Sciences and Morphofunctional Imaging, Section of Dermatology, University of Messina, Messina, ItalyUO Dermatologia, IRCCS Ospedale Galeazzi & Università degli Studi di Milano, Milan, ItalyDepartment of Dermatology, University of Bari, Bari, ItalyDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyDermatologic Unit, Department of Surgery, Infermi Hospital of Rimini, AUSL Romagna, Rimini, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyDepartment of Health Sciences, Dermatology Session, University of Florence, Florence, ItalyDivision of Dermatology, Psoriasis Outpatient Service, APSS – Azienda Provinciale per i Servizi Sanitari, Trento, ItalyDermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, ItalyDermatology Unit "Daniele Innocenzi", ASL Latina Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, ItalyDermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, ItalyDermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, ItalyDermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, ItalyDermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, ItalyDermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, ItalyPurpose of the article: The aim of this multicenter observational study is to report data from real world on the use of bimekizumab in patients aged ≥ 65 years with moderate-to-severe plaque psoriasis. Elderly patients are poorly represented in clinical trials on bimekizumab for plaque psoriasis, and real-world studies are important to guide clinical choices.Materials and methods: A retrospective multicenter study was conducted in 33 dermatological outpatient clinics in Italy. Patients aged ≥ 65 years, with moderate-to-severe plaque psoriasis and treated with bimekizumab were enrolled. No exclusion criteria were applied. Bimekizumab was administered following the Italian Guidelines for the management of plaque psoriasis and according to the summary of product characteristics, in adult patients who were candidates for systemic treatments. Overall, 98 subjects were included, and received bimekizumab up to week 36. Clinical and demographic data were collected before the initiation of treatment with bimekizumab. At baseline and each dermatological examination (4, 16, and 36 weeks), clinical outcomes were measured by the following parameters: (1) PASI score; (2) site-specific (scalp, palmoplantar, genital, nail) Psoriasis Global Assessment (PGA). At each visit, the occurrence of any adverse events (AEs) was recorded, including serious AEs and AEs leading to bimekizumab discontinuation.Results: The mean PASI score was 16.6 ± 9.4 at baseline and significantly decreased to 4.3 ± 5.2 after 4 weeks (p < 0.001), and 1.1 ± 1.7 after 16 week (p < 0.001). This level of improvement was maintained after 36 weeks (p < 0.001). PASI ≤2 was recorded in 36 (36.7%) at week 4, 68% and 69.4% at week 16 and 36, respectively. By week 16, 86/98 (87.8%) patients reached PASI75, 71/98 (72.4%) obtained PASI90, and 52/98 (53.1%) PASI100. Binary logistic regression tests showed a significant association of PASI100 by week 4 with lower PASI at baseline. PASI 100 at 16 or 36 weeks was not associated with baseline PASI, obesity, age, gender, previously naïve state, and presence of psoriatic arthritis. Patients naïve to biologics at baseline had similar response to bimekizumab as non-naïve subjects.Conclusions: Bimekizumab is a suitable option for elder patients as it is effective, tolerated and has a convenient schedule.https://www.tandfonline.com/doi/10.1080/09546634.2024.2393376Bimekizumabpsoriasiselderlycomorbidities |
| spellingShingle | D. Orsini M. Megna C. Assorgi A. Balato R. Balestri N. Bernardini A. Bettacchi T. Bianchelli L. Bianchi G. Buggiani M. Burlando AMG. Brunasso G. Caldarola N. Cameli A. Campanati E. Campione A. Carugno K. Chersi A. Conti A. Costanzo E. Cozzani A. Cuccia D. D’Amico G. Dal Bello E. G. Dall’Olio P. Dapavo C. De Simone E. V. Di Brizzi A. Di Cesare V. Dini M. Esposito E. Errichetti M. C. Fargnoli C. S. Fiorella A. Foti Z. Fratton F. M. Gaiani P. Gisondi R. Giuffrida A. Giunta C. Guarneri A. Legori F. Loconsole P. Malagoli A. Narcisi M. Paolinelli L. Potestio F. Prignano G. Rech A. Rossi N. Skroza F. Trovato M. Venturini A. G. Richetta G. Pellacani A. Dattola Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis) Journal of Dermatological Treatment Bimekizumab psoriasis elderly comorbidities |
| title | Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis) |
| title_full | Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis) |
| title_fullStr | Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis) |
| title_full_unstemmed | Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis) |
| title_short | Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis) |
| title_sort | efficacy and safety of bimekizumab in elderly patients real world multicenter retrospective study il pso italian landscape psoriasis |
| topic | Bimekizumab psoriasis elderly comorbidities |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2393376 |
| work_keys_str_mv | AT dorsini efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT mmegna efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT cassorgi efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT abalato efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT rbalestri efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT nbernardini efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT abettacchi efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT tbianchelli efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT lbianchi efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT gbuggiani efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT mburlando efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT amgbrunasso efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT gcaldarola efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT ncameli efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT acampanati efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT ecampione efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT acarugno efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT kchersi efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT aconti efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT acostanzo efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT ecozzani efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT acuccia efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT ddamico efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT gdalbello efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT egdallolio efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT pdapavo efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT cdesimone efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT evdibrizzi efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT adicesare efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT vdini efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT mesposito efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT eerrichetti efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT mcfargnoli efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT csfiorella efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT afoti efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT zfratton efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT fmgaiani efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT pgisondi efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT rgiuffrida efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT agiunta efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT cguarneri efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT alegori efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT floconsole efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT pmalagoli efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT anarcisi efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT mpaolinelli efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT lpotestio efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT fprignano efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT grech efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT arossi efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT nskroza efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT ftrovato efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT mventurini efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT agrichetta efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT gpellacani efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis AT adattola efficacyandsafetyofbimekizumabinelderlypatientsrealworldmulticenterretrospectivestudyilpsoitalianlandscapepsoriasis |